C07D 241/28
In which said hetero-bound carbon atoms have double bonds to oxygen, sulfur
Official title: in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
C07D241/28 (In which said hetero-bound carbon atoms have double bonds to oxygen, sulfur) appears on 128 US grants and 200 published applications in this corpus.
Search patents in C07D- Granted patents
- 128
- Published applications
- 200
- Assignees
- 68
- Inventors
- 364
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 1 | 6 |
| 2006 | 1 | 4 |
| 2007 | 4 | 1 |
| 2008 | 6 | 6 |
| 2009 | 0 | 8 |
| 2010 | 1 | 9 |
| 2011 | 2 | 6 |
| 2012 | 10 | 10 |
| 2013 | 8 | 10 |
| 2014 | 12 | 16 |
| 2015 | 11 | 14 |
| 2016 | 7 | 9 |
| 2017 | 8 | 15 |
| 2018 | 13 | 7 |
| 2019 | 9 | 13 |
| 2020 | 5 | 5 |
| 2021 | 5 | 10 |
| 2022 | 4 | 11 |
| 2023 | 5 | 9 |
| 2024 | 2 | 9 |
| 2025 | 8 | 11 |
| 2026 | 6 | 6 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Pyrazinecarboxamide analog compounds for use in treating cancer16 Jun 2026US 12,655,131 B2
- Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof26 May 2026US 12,637,435 B2FUJIFILM Corporation
- Inhibitors of SARM17 Apr 2026US 12,595,252 B2Disarm Therapeutics, Inc.
- Substituted benzamides for inhibiting perk activity31 Mar 2026US 12,590,064 B2Eli Lilly and Company
- Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist3 Feb 2026US 12,540,121 B2Arizona Board of Regents on behalf of Arizona State University
- Pyrazinecarboxamide analog compounds for use in treating cancer1 Oct 2026US 2026/0297064 A1Novapano LLC
- Gpr35 modulators30 Jul 2026US 2026/0216198 A1ThirtyFiveBio Limited
- Novel inhibitors of dna damage responses for cancer therapy23 Jul 2026US 2026/0209193 A1The Regents of the University of California
- Neutrophil elastase inhibitor and use thereof16 Jul 2026US 2026/0200845 A1Shanghai Yidi Biotechnology Co., Ltd
- Mixed mode charge induction ion exchange (iex) chromatography (mmciic) ligands and methods of use28 May 2026US 2026/0145159 A1Bio-Rad Laboratories, Inc.
Most cited
By later US patents
- Pyridine and pyrazine derivative for the treatment of CF76US 8,247,436 B2Novartis AG · 2012
- Phenyl guanidine sodium channel blockers69US 6,858,615 B2Parion Sciences, Inc. · 2005
- Compounds useful as inhibitors of ATR kinase57US 8,410,112 B2Vertex Pharmaceuticals Incorporated · 2013
- Sodium channel blockers55US 7,192,960 B2Parion Sciences, Inc. · 2007
- Sodium channel blockers53US 7,186,833 B2Parion Sciences, Inc. · 2007